Arcus Biosciences, Inc.RCUS
What Arcus Biosciences, Inc. does.
We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.
* Taiho holds exclusive licenses in Japan and certain other Asian countries, excluding China, for casdatifan (the “Taiho Territory”).
† Gilead and Arcus co-develop globally and share co-promotion rights in the U.S. for domvanalimab and quemliclustat. Gilead holds commercialization rights outside of the U.S. subject to Taiho’s rights for the Taiho Territory.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $78.0M | $383.0M | $112.0M | $117.0M | $258.0M | $247.0M |
| Net income | -$123.0M | $53.0M | -$267.0M | -$307.0M | -$283.0M | -$353.0M |
| Free cash flow | $108.0M | -$282.0M | $432.0M | -$330.0M | -$176.0M | -$484.0M |
More on RCUS.
- Arcus Biosciences, Inc. summary
- Arcus Biosciences, Inc. financial statements
- Arcus Biosciences, Inc. key metrics
- Arcus Biosciences, Inc. health scores and style box
- Arcus Biosciences, Inc. earnings
- Arcus Biosciences, Inc. dividends
- Arcus Biosciences, Inc. valuation
- Arcus Biosciences, Inc. ownership and insiders
- Arcus Biosciences, Inc. peers
Figures from Arcus Biosciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.